Research Papers:

Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo

Erfei Chen, Fangfang Yang, Hongjuan He, Lei Lei, Ruitao Liu, Le Du, Jing Dong, Meng Wang and Jin Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:19813-19823. https://doi.org/10.18632/oncotarget.7852

Metrics: PDF 1780 views  |   HTML 2106 views  |   ?  


Erfei Chen1,2, Fangfang Yang1, Hongjuan He1,2, Lei Lei1,2, Ruitao Liu1,2, Le Du1,2, Jing Dong1,2, Meng Wang1,2, Jin Yang1,2

1School of Life Sciences, Northwest University, Xi’an, P.R. China

2Institute of Preventive Genomic Medicine, Xi’an, P.R. China

Correspondence to:

Jin Yang, e-mail: [email protected]

Keywords: sporadic colorectal cancer, RASSF6, proliferation, apoptosis, loss-of-function mutation

Received: November 14, 2015     Accepted: February 11, 2016     Published: March 02, 2016


Ras-association domain family protein 6 (RASSF6) is a member of tumor suppressor RASSFs family with a wide range of function from RAS interaction, Hippo signaling involvement to cell cycle and apoptosis regulation. RASSF6 is reported inactivated in various types of cancer. However, whether RASSF6 is associated with colorectal cancer and the underlying mechanisms have yet to be investigated. In our previous exome sequencing study, we found a somatic loss-of-function (LoF) mutation in RASSF6 in one sporadic colorectal cancer (sCRC) patient, and two missense mutations in deep sequencing group of sCRC samples, implying the possibility that RASSF6 may be involved in the pathogenesis of sCRC. In this study, we demonstrate that RASSF6 acts as a tumor suppressor in colon cancer cells. Decreased level of RASSF6 was observed in adenocarcinoma compared to normal tissues, especially in advanced tumor cases. Further experiments showed exogenous introduction of RASSF6 into LoVo cells suppressed cell proliferation, migration, invasion, and induced apoptosis in vitro as well as tumor growth in vivo. In contrast, knockdown of RASSF6 in HT-29 cells showed the opposite effects. Taken together, our results suggest, in addition to epigenetics changes, functional somatic mutations may also contribute to the downregulation of RASSF6 and further participate in the pathogenesis of sCRC. RASSF6 may serve as a novel candidate against tumor growth for sCRC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7852